{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/contraception-assessment/management/comorbidities-special-situations/","result":{"pageContext":{"chapter":{"id":"10acf1be-13df-5c89-8f9c-6c905784040b","slug":"comorbidities-special-situations","fullItemName":"Scenario: Comorbidities and special situations","depth":2,"htmlHeader":"<!-- begin field b6fc91a2-ae04-4ce8-87d2-f825b8a42ae6 --><h2>Scenario: Comorbidities and special situations</h2><!-- end field b6fc91a2-ae04-4ce8-87d2-f825b8a42ae6 -->","summary":"Covers common situations that can influence the choice of contraceptive such as breastfeeding; postpartum; menorrhagia; diabetes; epilepsy; headache and migraine; hypertension; obesity; sexually transmitted infection; smoking; the presence of multiple risk factors for cardiovascular disease; and venous thromboembolism.","htmlStringContent":"<!-- begin item 21119df7-a261-4f14-9405-f146ba744ce0 --><!-- begin field 37b93ff8-ff00-4c76-86fc-acbc015a3ebd --><p>From age 13 years to 60 years (Female).</p><!-- end field 37b93ff8-ff00-4c76-86fc-acbc015a3ebd --><!-- end item 21119df7-a261-4f14-9405-f146ba744ce0 -->","topic":{"id":"b3143012-a228-55f5-8507-b5b650690e4c","topicId":"32f1df2c-afc0-4f35-be88-49caf8770b41","topicName":"Contraception - assessment","slug":"contraception-assessment","lastRevised":"Last revised in September 2019","chapters":[{"id":"8d7c8a25-4e93-5a42-928f-f6611bb74f8b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"f6467a38-cb74-5956-9113-c5ea6b3e26b3","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6121a83b-02e9-52ac-a8f9-0998004484bc","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"07b5f362-627f-5d8a-8d01-b917142582c2","slug":"changes","fullItemName":"Changes"},{"id":"0df9a885-e331-5bb2-aa56-e9c271c953dc","slug":"update","fullItemName":"Update"}]},{"id":"699be09a-1785-5ab5-bf3b-cf106ce69b83","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d59c7a2c-4736-5055-b01b-29e6039bc23b","slug":"goals","fullItemName":"Goals"},{"id":"8e96e0e4-38c0-5981-bfd3-d340e227337e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"df0725fd-cf61-5019-a02b-7c6e05ca6d55","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"86b18852-547f-5859-960f-b4512c2736c1","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"61cea463-ab64-5105-8179-666b624b775b","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8d52411f-5b91-53ff-87d9-703de7ff4ff1","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d6a02d9d-3223-585d-89bb-915cc73d1565","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"c6218ca2-8f9c-534f-95be-c1a373a78494","slug":"comparative-effectiveness-of-contraceptive-methods","fullItemName":"Comparative effectiveness of contraceptive methods"},{"id":"1e7241c0-cd2e-5c44-a7d0-01f505a5f6df","slug":"available-contraceptive-methods-in-the-uk","fullItemName":"Available contraceptive methods in the UK"}]},{"id":"f66ce071-5b93-583d-8904-2d6f862b75ea","fullItemName":"Management","slug":"management","subChapters":[{"id":"de31dc4a-7073-5d0b-83fb-9e0af6e49a7b","slug":"issues-to-consider-discuss","fullItemName":"Scenario: Issues to consider and discuss"},{"id":"10acf1be-13df-5c89-8f9c-6c905784040b","slug":"comorbidities-special-situations","fullItemName":"Scenario: Comorbidities and special situations"},{"id":"04a5ef68-fad9-5897-8a64-10294e5004a2","slug":"prescribing-to-young-people","fullItemName":"Scenario: Prescribing to young people"},{"id":"012d4729-63d2-51ca-a18c-bbd593b74fa4","slug":"approaching-the-menopause","fullItemName":"Scenario: Approaching the menopause"},{"id":"5970d6e3-da30-5c77-b143-090babc6df1b","slug":"assessment-for-specific-contraceptive-methods","fullItemName":"Scenario: Assessment for specific contraceptive methods"}]},{"id":"1f285502-649a-5805-a56d-1819aafe2ef0","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"2c624d48-ad5c-53e5-afd7-03cbcb0af45d","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"040eb257-bbbd-5695-8eda-cde5a6b0991e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"582f4ca4-299f-54d7-ac03-285acee6a6d6","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"c6171063-570c-5710-a837-052779620da6","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"278eb9ce-8d46-577d-bc1b-19866cb57433","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7e6a7d96-a9eb-5bb8-bb74-9a82eb3efeaa","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"83baf2bb-d418-5417-9e87-94f055e1ea8a","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"f66ce071-5b93-583d-8904-2d6f862b75ea","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"a8ae27ba-0594-5da3-b3e9-a7ad19b1fc17","slug":"breastfeeding","fullItemName":"Breastfeeding","depth":3,"htmlHeader":"<!-- begin field d4b049a0-e298-4196-be66-c0d781740a56 --><h3>What methods of contraception are suitable for a woman who is breastfeeding?</h3><!-- end field d4b049a0-e298-4196-be66-c0d781740a56 -->","summary":null,"htmlStringContent":"<!-- begin item 09baa779-4b37-42ee-b288-d5d737ee7796 --><!-- begin field 017b39aa-9cbc-4279-9ab6-8fc6474b9f4d --><ul><li>Contraception is not needed in the first 20 days after delivery, but is required from day 21 if the woman is not fully breastfeeding and does not want to become pregnant.</li><li><strong>If the woman is breastfeeding and is less than 6 weeks postpartum:</strong><ul><li>Discuss the following methods of contraception, taking into account her personal circumstances, and how important it is that she avoids pregnancy:<ul><li>Barrier methods (condoms only) — diaphragms and cervical caps are unsuitable less than 6 weeks postpartum, until uterine involution is complete.</li><li>Progestogen-only pills (POPs), progestogen-only implants, or progestogen-only injectables.</li><li>A copper intrauterine device (Cu-IUD) or the levonorgestrel intrauterine system (LNG-IUS), from 4 weeks postpartum (off-label use). </li></ul></li><li>Consider the following methods before 4 weeks postpartum (off-label use), only after seeking specialist advice as the risks (uterine perforation) usually outweigh the benefits:<ul><li>Cu-IUD or LNG-IUS.</li></ul></li><li>Do not use the following methods:<ul><li>Combined hormonal contraceptives (pill, transdermal patch, or vaginal ring).</li><li>Female sterilization — delay until the woman is 6 weeks or more postpartum. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-sterilization/\">Contraception - sterilization</a>.</li></ul></li></ul></li><li><strong>If the woman is fully or almost fully breastfeeding and is between 6 weeks and 6 months postpartum:</strong><ul><li>Discuss the following methods of contraception, taking into account her personal circumstances, and how important it is that she avoids pregnancy:<ul><li>Barrier methods (condoms, diaphragms, and caps).</li><li>The POP, progestogen-only injectables, and implants.</li><li>Cu-IUD or LNG-IUS.</li><li>Combined hormonal contraceptives (pill, transdermal patch, and vaginal ring).</li><li>Female sterilization.</li></ul></li></ul></li><li><strong>If the woman is breastfeeding and is 6 months or more postpartum:</strong><ul><li>All methods can be used.</li><li>For a woman who is postpartum and not breastfeeding, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/contraception-assessment/management/comorbidities-special-situations/#postpartum-not-breastfeeding\">Postpartum and not breastfeeding</a>.</li></ul></li></ul><!-- end field 017b39aa-9cbc-4279-9ab6-8fc6474b9f4d --><!-- end item 09baa779-4b37-42ee-b288-d5d737ee7796 -->","subChapters":[{"id":"5af9b2e4-855c-5ade-baf5-9ada683bddb9","slug":"basis-for-recommendation-e41","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 0d3571af-6c4f-435d-8fac-70c9b9e46160 --><h4>Basis for recommendation</h4><!-- end field 0d3571af-6c4f-435d-8fac-70c9b9e46160 -->","summary":null,"htmlStringContent":"<!-- begin item e41150e2-d07b-4a2d-ad41-e81b20c93903 --><!-- begin field 6bf28581-efff-4c2f-a15d-36693ae23502 --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) guideline <em>UK Medical Eligibility Criteria for contraceptive u</em><em>se</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2016</a>]<em> a</em>nd the World Health Organization (WHO) guidance<em> Medical eligibility for contraceptive use</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">WHO, 2015</a>].</p><p><strong>Postpartum use of an intrauterine device </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2016</a>]</p><ul><li>The most important risk factors for uterine perforation are insertion: <ul><li>In breastfeeding women, where the risk of perforation is six times higher.  </li><li>Within 36 weeks of giving birth. </li></ul></li></ul><!-- end field 6bf28581-efff-4c2f-a15d-36693ae23502 --><!-- end item e41150e2-d07b-4a2d-ad41-e81b20c93903 -->","subChapters":[]}]},{"id":"d86ff02c-2f00-5c3e-aeb8-c711ee140ef9","slug":"epilepsy","fullItemName":"Epilepsy","depth":3,"htmlHeader":"<!-- begin field f2fcf991-30ec-412c-9424-aece96131b1e --><h3>What methods of contraception are suitable for a woman with epilepsy?</h3><!-- end field f2fcf991-30ec-412c-9424-aece96131b1e -->","summary":null,"htmlStringContent":"<!-- begin item 48431a0c-8a23-4ad7-b74a-1d1ba837603b --><!-- begin field 9c93100b-939f-430d-9b50-387bf39d938b --><ul><li><strong>For women who are not taking liver enzyme-inducing drugs:</strong><ul><li>All methods can be used. However, only consider female sterilization if epilepsy is adequately controlled (WHOMEC C).</li></ul></li><li><strong>For women taking liver enzyme-inducing drugs (such as phenytoin, carbamazepine, barbiturates, primidone, or topiramate):</strong><ul><li>Discuss the following methods of contraception, taking into account her personal circumstances, and how important it is that she avoids pregnancy: <ul><li>Barrier methods (condoms, diaphragms, and caps). </li><li>Copper intrauterine device (Cu-IUD) or levonorgestrel intrauterine system (LNG-IUS).</li><li>Progestogen-only injectables.</li><li>Female sterilization — if epilepsy is adequately controlled (WHOMEC C).</li></ul></li><li>Topiramate is associated with a risk of fetal malformations and can impair the effectiveness of hormonal contraceptives. Before initiating topiramate in a woman of childbearing potential, pregnancy testing should be performed. The patient should be fully informed of the risks related to the use of topiramate during pregnancy. Ensure that women and girls of childbearing potential are advised that they should be using a highly effective method of contraception. Topiramate is a weak enzyme inducer, but the contraceptive efficacy of the COC may be unaffected by topiramate doses lower than 200 mg daily.  </li><li>If a woman wishes to use combined hormonal contraception (pill, transdermal patch, or vaginal ring), see the section on drug interactions (for the <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/management/combined-oral-contraceptive/#drug-interactions\">pill</a>, <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/management/combined-contraceptive-patch/#drug-interactions\">patch</a>, or <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/management/combined-contraceptive-vaginal-ring/#drug-interactions\">ring</a>) in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a></li><li>If a woman wishes to use the progestogen-only pill, or progestogen-only implant, see the section on drug interactions (for the <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/management/progestogen-only-pill/#drug-interactions\">pill</a> or the <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/management/progestogen-only-implant/#drug-interactions\">implant</a>) in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li><li><strong>For women taking lamotrigine: </strong><ul><li>Discuss the following methods of contraception, taking into account her personal circumstances, and how important it is that she avoids pregnancy: <ul><li>Barrier methods (condoms, diaphragms, and caps).</li><li>Cu-IUD or the LNG-IUS.</li><li>Progestogen-only pill, progestogen-only implant, or progestogen-only injectable.</li><li>Female sterilization — if epilepsy is adequately controlled (WHOMEC C).</li></ul></li><li>Advise the woman not to use a combined hormonal contraceptive (CHC) if taking lamotrigine monotherapy, as it may lower the seizure control. For more information, see the section on drug interactions (for the <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/management/combined-oral-contraceptive/#drug-interactions\">pill</a>, <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/management/combined-contraceptive-patch/#drug-interactions\">patch</a>, or <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/management/combined-contraceptive-vaginal-ring/#drug-interactions\">ring</a>) in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a>. <ul><li>If the woman is taking lamotrigine in combination with sodium valproate, CHC is unlikely to affect seizure control.</li></ul></li></ul></li></ul><!-- end field 9c93100b-939f-430d-9b50-387bf39d938b --><!-- end item 48431a0c-8a23-4ad7-b74a-1d1ba837603b -->","subChapters":[{"id":"5cb850bc-a293-5f75-a76e-4fca5e74a666","slug":"basis-for-recommendation-176","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 73bbd5bf-e6d4-4773-b07a-94f2fa5c7cde --><h4>Basis for recommendation</h4><!-- end field 73bbd5bf-e6d4-4773-b07a-94f2fa5c7cde -->","summary":null,"htmlStringContent":"<!-- begin item 1768df21-9738-4cd0-b156-67bf19adfe34 --><!-- begin field a673f48e-25b4-4c05-94ae-8e2233c59c29 --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline <em>Drug interactions with hormonal contraception </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2011b</a>]<em>,</em><em> the UK Medical Eligibility Criteria for contraceptive use</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2016</a>]<em>,</em><em> </em>the World Health Organization (WHO) guidance <em>Medical eligibility for contraceptive use</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">WHO, 2015</a>], and the manufacturer's Summary of Product Characteristics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">ABPI, 2017</a>].</p><!-- end field a673f48e-25b4-4c05-94ae-8e2233c59c29 --><!-- end item 1768df21-9738-4cd0-b156-67bf19adfe34 -->","subChapters":[]}]},{"id":"613bf150-3574-5586-9cbe-ae5ffcc98999","slug":"postpartum-not-breastfeeding","fullItemName":"Postpartum and not breastfeeding","depth":3,"htmlHeader":"<!-- begin field 006afc89-8205-4c70-98d1-5b822380db16 --><h3>What methods of contraception are suitable if a woman is postpartum and not breastfeeding?</h3><!-- end field 006afc89-8205-4c70-98d1-5b822380db16 -->","summary":null,"htmlStringContent":"<!-- begin item 7a4b6efd-ebaa-474f-9045-29937ed0fe4e --><!-- begin field 8808fac5-9ea7-4b0d-815b-480843e169f6 --><ul><li>Contraception is not needed in the first 20 days after delivery, but it is required from day 21 if the woman does not want to become pregnant.</li><li><strong>For a woman who is less than 21 days postpartum:</strong><ul><li>Discuss the following methods of contraception, taking into account her personal circumstances, and how important it is that she avoids pregnancy:<ul><li>Barrier methods (condoms only) — diaphragms and caps are unsuitable less than 6 weeks postpartum, until uterine involution is complete.</li><li>Progestogen-only pill (POP), progestogen-only injectable, or progestogen-only implant.</li></ul></li><li>Consider the following method only after seeking specialist advice as the risks usually outweigh the benefits:<ul><li>Copper intrauterine device (Cu-IUD) or levonorgestrel intrauterine device (LNG-IUS).</li><li>Combined hormonal contraception (pill, transdermal patch, or vaginal ring) if there are no other risks for venous thromboembolism (VTE). </li></ul></li><li>Do not use the following methods:<ul><li>Combined hormonal contraception (pill, transdermal patch, or vaginal ring) if there are other risks for VTE.</li><li>Sterilization — delay until the woman is 6 weeks or more postpartum.</li></ul></li></ul></li><li><strong>For a woman who is 21 days or more postpartum:</strong><ul><li>Discuss the following methods of contraception, taking into account her personal circumstances, and how important it is that she avoids pregnancy: <ul><li>Barrier methods — diaphragms and caps are unsuitable less than 6 weeks postpartum.  </li><li>Combined hormonal contraception (pill, transdermal patch, or vaginal ring) — if there are no other risks for VTE. </li><li>POP, progestogen-only injectables or progestogen-only implants.</li><li>Cu-IUD, or LNG-IUS — from 4 weeks postpartum (off-label use).</li><li>Sterilization — from 6 weeks postpartum.</li></ul></li><li>If there are other risks for VTE, only consider combined hormonal contraception after seeking specialist advice.</li></ul></li></ul><!-- end field 8808fac5-9ea7-4b0d-815b-480843e169f6 --><!-- end item 7a4b6efd-ebaa-474f-9045-29937ed0fe4e -->","subChapters":[{"id":"0b1d2b71-d866-55a1-8746-a958c5b8d4e2","slug":"basis-for-recommendation-4d9","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field a0b8a336-1673-4a1f-bee8-9b3b20f29f59 --><h4>Basis for recommendation</h4><!-- end field a0b8a336-1673-4a1f-bee8-9b3b20f29f59 -->","summary":null,"htmlStringContent":"<!-- begin item 4d94b5d5-ef6c-40f3-9bf6-9b0fe34637bb --><!-- begin field 89f5945d-da81-4e2e-81a1-28571e8178c0 --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) guideline <em>UK </em><em>Medical Eligibility Criteria for contraceptive use</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2016</a>]<em>, </em>the World Health Organization (WHO) guidance <em>Medical eligibility for contraceptive use</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">WHO, 2015</a>], and the Summary of Product Characteristics for Mirena® [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">ABPI, 2015</a>].</p><h5>Intrauterine contraception use postpartum</h5><ul><li>The FSRH advises that the copper intrauterine device (Cu-IUD) and the levonorgestrel intrauterine system (LNG-IUS) can be inserted at least 4 weeks postpartum. <ul><li>However, the manufacturers of Mirena® recommend that insertion should be delayed until 6 weeks postpartum [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">ABPI, 2015</a>].</li></ul></li></ul><!-- end field 89f5945d-da81-4e2e-81a1-28571e8178c0 --><!-- end item 4d94b5d5-ef6c-40f3-9bf6-9b0fe34637bb -->","subChapters":[]}]},{"id":"ecaf4cde-4e37-50b9-948f-5bd61848ec02","slug":"menorrhagia-fibroids-or-previous-ectopic-pregnancy","fullItemName":"Menorrhagia, fibroids or previous ectopic pregnancy","depth":3,"htmlHeader":"<!-- begin field e81848a5-d167-4da8-90c7-33a34a01daf3 --><h3>What methods of contraception are suitable for a woman with menorrhagia, fibroids, or a previous ectopic pregnancy?</h3><!-- end field e81848a5-d167-4da8-90c7-33a34a01daf3 -->","summary":null,"htmlStringContent":"<!-- begin item 5ed84fec-5616-4adc-b894-561f99c18a37 --><!-- begin field e2a57d88-b32e-48dc-9b2d-36c2dcb65b18 --><ul><li><strong>For women with idiopathic menorrhagia:</strong><ul><li>All methods can be used.</li><li>Consider recommending:<ul><li>The levonorgestrel intrauterine system (LNG-IUS) first-line.</li><li>The combined oral contraceptive (COC) pill second-line.</li><li>The progestogen-only pill (POP) and progestogen-only injectables third-line.</li></ul></li><li>For information on non-contraceptive treatments, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/menorrhagia/\">Menorrhagia</a>.</li></ul></li><li><strong>For women with unexplained vaginal bleeding:</strong> <ul><li>Investigate all unexplained vaginal bleeding to rule out any underlying conditions such as pregnancy or malignancy. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/gynaecological-cancers-recognition-referral/\">Gynaecological cancers - recognition and referral</a>.</li><li>Discuss the following methods of contraception, taking into account her personal circumstances, and how important it is that she avoids pregnancy:<ul><li>Barrier methods (condoms, diaphragms, and caps).</li><li>Combined hormonal contraception (pill, transdermal patch, and vaginal ring).</li><li>The POP.</li><li>The copper intrauterine device (Cu-IUD) or LNG-IUS if use is being continued.</li></ul></li><li>Consider the following methods only after seeking specialist advice:<ul><li>Progestogen-only implants and progestogen-only injectables.</li></ul></li><li>Do not use the following methods:<ul><li>Cu-IUD or LNG-IUS if initiating contraception.</li><li>Sterilization — this should be delayed until the bleeding is investigated (WHOMEC D).</li></ul></li></ul></li><li><strong>For women with a history of ectopic pregnancy, </strong><strong>all methods can be used without restriction.</strong></li><li><strong>For women with uterine fibroids:</strong><ul><li><strong>Without </strong>distortion of the uterine cavity —all methods can be used.<ul><li>However, depending on the location and size of the fibroid, sterilization may be difficult (WHOMEC C).</li></ul></li><li><strong>With </strong>distortion of the uterine cavity — advise the woman to use one of the following methods:<ul><li>Barrier methods (condoms, diaphragms, and caps).</li><li>Combined hormonal contraception (pill, transdermal patch, or combined vaginal ring).</li><li>Progestogen-only pill (POP), progestogen-only implant, or progestogen-only injectable.</li><li>Female sterilization — depending on the location and size of the fibroid, sterilization may be difficult (WHOMEC C).</li></ul></li><li>Consider the following methods only after seeking specialist advice as the risks usually outweigh the benefits:<ul><li>Cu-IUD or LNG-IUS — these may be difficult to fit.</li></ul></li></ul></li></ul><!-- end field e2a57d88-b32e-48dc-9b2d-36c2dcb65b18 --><!-- end item 5ed84fec-5616-4adc-b894-561f99c18a37 -->","subChapters":[{"id":"4d95eb8c-6f2f-5edd-b16e-a9326c855efb","slug":"basis-for-recommendation-837","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field a21ca773-d9bc-49f1-a194-7d37ce349158 --><h4>Basis for recommendation</h4><!-- end field a21ca773-d9bc-49f1-a194-7d37ce349158 -->","summary":null,"htmlStringContent":"<!-- begin item 837d7883-9cdb-4109-a966-2b6a545e9b77 --><!-- begin field fa8a4528-a712-4431-a6f6-0a950cb7b5c6 --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) guideline <em>UK Medical Eligibility Criteria for contraceptive use</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2016</a>]<em>, </em>the World Health Organization (WHO) guidance <em>Medical eligibility for contraceptive use</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">WHO, 2015</a>] and the manufacturer's Summary of Product Characteristics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">ABPI, 2016b</a>].</p><ul><li>The UK Medical Eligibility Criteria advises that the combined vaginal ring can be used in women with unexplained vaginal bleeding, before evaluation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2016</a>]. <ul><li>However, the manufacturers of Nuvaring® advise that it should not be initiated or continued in women with undiagnosed vaginal bleeding [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">ABPI, 2016b</a>].</li></ul></li></ul><!-- end field fa8a4528-a712-4431-a6f6-0a950cb7b5c6 --><!-- end item 837d7883-9cdb-4109-a966-2b6a545e9b77 -->","subChapters":[]}]},{"id":"0d941a04-132b-5ee8-bef2-83abaad8d05c","slug":"diabetes-mellitus","fullItemName":"Diabetes mellitus","depth":3,"htmlHeader":"<!-- begin field d32695ca-8cf4-4f3f-9839-5b0d20e7917c --><h3>What methods of contraception are suitable for a woman with diabetes mellitus?</h3><!-- end field d32695ca-8cf4-4f3f-9839-5b0d20e7917c -->","summary":null,"htmlStringContent":"<!-- begin item fe59be6f-c4f8-4887-afa4-99a937e4eb63 --><!-- begin field 15f0849f-ac53-4886-80a6-adc25fb533ba --><ul><li><strong>For a woman with diabetes mellitus (insulin and non–insulin dependent) and no vascular disease:</strong><ul><li>All methods can be used. However, only consider: <ul><li>Female sterilization (WHOMEC C) if well controlled, as there is a risk of hypoglycaemia or ketoacidosis.</li></ul></li></ul><strong>For a woman with diabetes mellitus and nephropathy, retinopathy, neuropathy, or other vascular disease:</strong><ul><li>Discuss the following methods of contraception, taking into account her personal circumstances, and how important it is that she avoids pregnancy: <ul><li>Barrier methods (condoms, diaphragms, and caps).</li><li>Copper intrauterine device (Cu-IUD) or levonorgestrel intrauterine system (LNG-IUS).</li><li>Progestogen-only pill (POP), progestogen-only implants, or progestogen-only injectables.</li></ul></li><li>Consider the following methods only after seeking specialist advice as the risks usually outweigh the benefits:<ul><li>Combined hormonal contraceptives (pill, transdermal patch and vaginal ring) — use clinical judgement to determine the appropriate classification.</li><li>Female sterilization (WHOMEC S) — women with diabetes are more likely to have complications when undergoing sterilization. </li></ul></li></ul></li><li><strong>For a woman with a history of gestational diabetes, all</strong> <strong>methods can be used without restriction.</strong></li></ul><!-- end field 15f0849f-ac53-4886-80a6-adc25fb533ba --><!-- end item fe59be6f-c4f8-4887-afa4-99a937e4eb63 -->","subChapters":[{"id":"5b48bf36-c0d3-5f66-9201-db0751c34c7a","slug":"basis-for-recommendation-db0","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field ff5f81a0-9cca-44e2-9f35-5931061a972e --><h4>Basis for recommendation</h4><!-- end field ff5f81a0-9cca-44e2-9f35-5931061a972e -->","summary":null,"htmlStringContent":"<!-- begin item db0f9f7e-5b27-453d-b93d-b93af214fd8a --><!-- begin field c0885e25-647a-4b9f-988c-66730b45d992 --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) guideline <em>UK Medical Eligibility Criteria for contraceptive use</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2016</a>]<em> </em>and the World Health Organization (WHO) guidance <em>Medical eligibility for contraceptive use </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">WHO, 2015</a>].</p><!-- end field c0885e25-647a-4b9f-988c-66730b45d992 --><!-- end item db0f9f7e-5b27-453d-b93d-b93af214fd8a -->","subChapters":[]}]},{"id":"64b18bff-cbc7-59e3-89c6-33dc5dba3d44","slug":"headache-or-migraine","fullItemName":"Headache or migraine","depth":3,"htmlHeader":"<!-- begin field 56a2b80e-6c24-4555-b4d2-addc7a19c61d --><h3>What methods of contraception are suitable for a woman with headache or migraine?</h3><!-- end field 56a2b80e-6c24-4555-b4d2-addc7a19c61d -->","summary":null,"htmlStringContent":"<!-- begin item c4d560ec-1e4c-4186-8b6a-461c463f692c --><!-- begin field 5bd6e8e0-408c-4ad7-a0ff-4d03e46b7d5b --><ul><li><strong>For a woman with non-migrainous headaches:</strong><ul><li>All methods can be used.</li></ul></li><li><strong>For a woman with migraine without aura:</strong><ul><li>Discuss the following methods of contraception, taking into account her personal circumstances, and how important it is that she avoids pregnancy: <ul><li>Barrier methods (condoms, diaphragms, and caps).</li><li>Copper intrauterine device (Cu-IUD) or levonorgestrel intrauterine system (LNG-IUS).</li><li>Progestogen-only pill (POP), progestogen-only implants, or progestogen-only injectable.</li><li>Combined hormonal contraceptives (pill, patch, and vaginal ring) can be considered if they are being initiated.</li><li>Female sterilization.</li></ul></li><li>Consider the following methods only after seeking specialist advice, as the risks usually outweigh the benefits:<ul><li>Continuation of combined hormonal contraceptives (pill, transdermal patch, and vaginal ring).</li></ul></li></ul></li><li><strong>For a woman with migraine with aura:</strong><ul><li>Discuss the following methods of contraception, taking into account her personal circumstances, and how important it is that she avoids pregnancy:<ul><li>Barrier methods (condoms, diaphragms, and caps).</li><li>Cu-IUD or LNG-IUS.</li><li>POP, progestogen-only implants, or progestogen-only injectable.</li><li>Female sterilization.</li></ul></li><li>Do not use the following methods due to unacceptable health risk:<ul><li>Combined hormonal contraceptives (pill, transdermal patch, or vaginal ring).</li></ul></li></ul></li><li><strong>For a woman with a past history (5 years or more) of migraine with aura:</strong><ul><li>Discuss the following methods of contraception, taking into account her personal circumstances, and how important it is that she avoids pregnancy:<ul><li>Barrier methods (condoms, diaphragms, and caps).</li><li>Cu-IUD or LNG-IUS.</li><li>Progestogen-only pill (POP), implants, and injectables.</li><li>Female sterilization.</li></ul></li><li>Consider the following methods only after seeking specialist advice, as the risks usually outweigh the benefits:<ul><li>Combined hormonal contraceptives (pill, patch, and vaginal ring).</li></ul></li></ul></li><li><strong>Definition of aura</strong><ul><li>Aura are focal neurological symptoms (due to cerebral ischaemia) that start before the headache, such as visual disturbances (for example homonymous hemianopia), unilateral paraesthesia and/or numbness, unilateral weakness, and aphasia, or unclassifiable speech disorder. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/migraine/\">Migraine</a>.</li></ul></li></ul><!-- end field 5bd6e8e0-408c-4ad7-a0ff-4d03e46b7d5b --><!-- end item c4d560ec-1e4c-4186-8b6a-461c463f692c -->","subChapters":[{"id":"c9694ca5-7561-5cd4-a052-4cdc61524725","slug":"basis-for-recommendation-43e","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 6825f80f-bfb3-4f0b-a8a4-f65a63dacdac --><h4>Basis for recommendation</h4><!-- end field 6825f80f-bfb3-4f0b-a8a4-f65a63dacdac -->","summary":null,"htmlStringContent":"<!-- begin item 43e062bb-cef4-48d9-bee9-aa75fad8db72 --><!-- begin field 980f1034-c44d-4b56-8054-67f1ba925750 --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) guideline <em>UK Medical Eligibility Criteria for contraceptive use</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2016</a>]<em> </em>and the World Health Organization (WHO) guidance <em>Medical eligibility for contraceptive use</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">WHO, 2015</a>].</p><p><strong>Migraine and stroke risk </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2016</a>]:</p><ul><li>Women who have aura are at a higher risk of stroke than those without aura. </li><li>Women with a history of migraine who use combined oral contraceptives are about two to four times as likely to have an ischaemic stroke as non-users with a history of migraine.</li></ul><!-- end field 980f1034-c44d-4b56-8054-67f1ba925750 --><!-- end item 43e062bb-cef4-48d9-bee9-aa75fad8db72 -->","subChapters":[]}]},{"id":"e9b808cc-c2cd-5707-b1a9-a99a67a361d7","slug":"multiple-risk-factors-for-cardiovascular-disease","fullItemName":"Multiple risk factors for cardiovascular disease","depth":3,"htmlHeader":"<!-- begin field b085ba1a-afd0-4a82-a80a-040a0fad79e2 --><h3>What methods of contraception are suitable for a woman with multiple risk factors for cardiovascular disease?</h3><!-- end field b085ba1a-afd0-4a82-a80a-040a0fad79e2 -->","summary":null,"htmlStringContent":"<!-- begin item ab3ca399-707e-4885-a0a7-67d6d96b6ee3 --><!-- begin field 4120c96e-dd27-49b5-9b5d-ae64172b4e7f --><p><strong>For a woman with multiple risk factors for cardiovascular disease (such as women aged over 35 years, smoking, diabetes, hypertension, and obesity):</strong></p><ul><li>Discuss the following methods of contraception, taking into account her personal circumstances, and how important it is that she avoids pregnancy:<ul><li>Barrier methods (condoms, diaphragms, and caps). <ul><li>However, advise woman using the diaphragm to seek advice regarding diaphragm fitting if they gain or lose 3 kg or more in weight. For more information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/contraception-assessment/management/comorbidities-special-situations/#obesity\">Obesity</a>.</li></ul></li><li>Copper intrauterine device (Cu-IUD) or the levonorgestrel intrauterine system (LNG-IUS).</li><li>Progestogen-only pill (POP) or progestogen-only implants.</li></ul></li><li>Consider the following methods only after seeking specialist advice:<ul><li>Progestogen-only injectables.</li><li>Combined hormonal contraception (CHC). For more information see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/contraception-assessment/management/comorbidities-special-situations/#chcs-multiple-risk-factors-for-cvd\">CHCs and multiple risk factors for CVD</a>.</li><li>Female sterilization (WHOMEC S).</li></ul></li><li>For information on management and contraceptive choice in women who have cardiovascular disease, see the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline <a href=\"https://www.fsrh.org/documents/ceu-guidance-contraceptive-choices-for-women-with-cardiac/\" data-hyperlink-id=\"6a34fc60-378e-4ec1-adfa-a99201267cb8\">Contraceptive choices for women with cardiac disease</a>.</li></ul><!-- end field 4120c96e-dd27-49b5-9b5d-ae64172b4e7f --><!-- end item ab3ca399-707e-4885-a0a7-67d6d96b6ee3 -->","subChapters":[{"id":"125fa1d8-4c1b-5567-a992-8413a33c8a02","slug":"chcs-multiple-risk-factors-for-cvd","fullItemName":"CHCs and multiple risk factors for CVD","depth":4,"htmlHeader":"<!-- begin field a6c9c018-443e-4bd2-ab9c-a6bf00d74f85 --><h4>CHCs and multiple risk factors for CVD</h4><!-- end field a6c9c018-443e-4bd2-ab9c-a6bf00d74f85 -->","summary":null,"htmlStringContent":"<!-- begin item 3fd823de-9b0a-4335-b843-a6bf00d74e45 --><!-- begin field 66303bd1-c094-4ce0-9dfe-a6bf00d74f85 --><ul><li>CHC may be contraindicated depending on the number and severity of risk factors. Clinical judgement should be used to decide on a suitable method of contraception, however, CHC should be avoided if:<ul><li>Any one of the following risk factors are present:<ul><li>Obesity — body mass index ≥ 35 kg/m<sup>2</sup> (unless there is no suitable alternative).</li><li>Smoking — 40 or more cigarettes daily.</li><li>Diabetes mellitus — if complications are present.</li><li>Family history of arterial disease in first degree relative aged under 45 years — if atherogenic lipid profile.</li><li>Hypertension —blood pressure above or equal to systolic 160 mmHg or diastolic 100 mmHg.</li><li>Migraine — with aura (focal symptoms), or severe migraine frequently lasting over 72 hours despite treatment, or migraine treated with ergot derivative.</li></ul></li><li>Any two or more of the following risk factors are present:<ul><li>Obesity (body mass index ≥ 30 kg/m<sup>2</sup>).</li><li>Smoking.</li><li>Diabetes mellitus.</li><li>Family history of arterial disease in first degree relative aged under 45 years. </li><li>Hypertension—blood pressure above systolic 140 mmHg or diastolic 90 mmHg.</li><li>Migraine without aura.</li></ul></li></ul></li></ul><!-- end field 66303bd1-c094-4ce0-9dfe-a6bf00d74f85 --><!-- end item 3fd823de-9b0a-4335-b843-a6bf00d74e45 -->","subChapters":[]},{"id":"6fbe6b87-c59c-5708-8921-ffdf9f7bbe99","slug":"basis-for-recommendation-e94","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field faad7622-3495-4dfc-b5fa-5206eaf4691b --><h4>Basis for recommendation</h4><!-- end field faad7622-3495-4dfc-b5fa-5206eaf4691b -->","summary":null,"htmlStringContent":"<!-- begin item e9432318-3e23-49ab-93d7-79e7b77c5783 --><!-- begin field 5bdad6d2-c9cd-4abc-b668-6d5268c5e294 --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) guideline <em>UK Medical Eligibility Criteria for contraceptive use</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2016</a>]<em>, </em>the World Health Organization (WHO) guidance <em>Medical eligibility for contraceptive use</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">WHO, 2015</a>], and the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">BNF 71, 2016</a>].</p><!-- end field 5bdad6d2-c9cd-4abc-b668-6d5268c5e294 --><!-- end item e9432318-3e23-49ab-93d7-79e7b77c5783 -->","subChapters":[]}]},{"id":"3e09c73f-9782-578d-9310-6f1880a63017","slug":"smoking","fullItemName":"Smoking","depth":3,"htmlHeader":"<!-- begin field 524c7974-5a5a-465f-9d1b-f59e0647f3a1 --><h3>What methods of contraception are suitable for a woman who smokes?</h3><!-- end field 524c7974-5a5a-465f-9d1b-f59e0647f3a1 -->","summary":null,"htmlStringContent":"<!-- begin item a1ccd059-e9a9-45d1-bc49-d9a974817601 --><!-- begin field 3451aa71-4c46-4625-be8a-9387f5c2b5f2 --><ul><li><strong>For a woman who is younger than 35 years of age and is currently smoking, or a woman who is 35 years of age or older and stopped smoking 12 months ago or longer:</strong><ul><li>All methods can be used. </li></ul></li><li><strong>For a woman who is 35 years of age or older and smokes less than 15 cigarettes daily, or has stopped smoking in the past 12 months:</strong><ul><li>Discuss the following methods of contraception, taking into account her personal circumstances, and how important it is that she avoids pregnancy:<ul><li>Barrier methods (condoms, diaphragms, and caps).</li><li>Copper intrauterine device (Cu-IUD) or the levonorgestrel intrauterine system (LNG-IUS).</li><li>Progestogen-only pill (POP), progestogen-only injectables, and progestogen-only implants.</li><li>Female sterilization.</li></ul></li><li>Consider combined hormonal contraceptives (pill, transdermal patch and vaginal ring) only after seeking specialist advice as the risks usually outweigh the benefits.<ul></ul></li></ul></li><li><strong>For a women who is 35 years or older and smokes 15 cigarettes or more daily:</strong><ul><li>Discuss the following methods of contraception, taking into account her personal circumstances, and how important it is that she avoids pregnancy:<ul><li>Barrier methods (condoms, diaphragms, and caps) — can be used alone or in addition to other suitable methods.</li><li>Cu-IUD or LNG-IUS.  </li><li>POP, progestogen-only injectables, and progestogen-only implants.</li><li>Female sterilization.</li></ul></li><li>Do not use the combined hormonal contraceptives (pill, patch and vaginal ring) due to the unacceptable health risk.<ul></ul></li></ul></li></ul><!-- end field 3451aa71-4c46-4625-be8a-9387f5c2b5f2 --><!-- end item a1ccd059-e9a9-45d1-bc49-d9a974817601 -->","subChapters":[{"id":"1c1c6228-aadf-56c4-a910-5ecc3b3f64c0","slug":"basis-for-recommendation-adb","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 18ec25ed-f680-4f46-a6e4-73a20b6a22df --><h4>Basis for recommendation</h4><!-- end field 18ec25ed-f680-4f46-a6e4-73a20b6a22df -->","summary":null,"htmlStringContent":"<!-- begin item adb26ac3-59db-439f-9979-be6dbc782d5a --><!-- begin field e55df689-64a0-45a0-a6f5-b6ba09460211 --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2016</a>] and the World Health Organization (WHO) guidance <em>Medical eligibility for contraceptive use </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">WHO, 2015</a>].</p><!-- end field e55df689-64a0-45a0-a6f5-b6ba09460211 --><!-- end item adb26ac3-59db-439f-9979-be6dbc782d5a -->","subChapters":[]}]},{"id":"a5343a33-0030-5c58-8985-b797a55948fc","slug":"sti-or-pelvic-inflammatory-disease","fullItemName":"STI or pelvic inflammatory disease","depth":3,"htmlHeader":"<!-- begin field 1746d968-80b5-40a3-8520-88ab706882f0 --><h3>What methods of contraception are suitable for a woman with a sexually transmitted infection (STI) or pelvic inflammatory disease (PID)?</h3><!-- end field 1746d968-80b5-40a3-8520-88ab706882f0 -->","summary":null,"htmlStringContent":"<!-- begin item 9b95e29e-7cd7-4fbe-be64-35b80bbc5ff7 --><!-- begin field 8729dbe4-4381-4dd2-94bb-6c4969f89730 --><ul><li><strong>For women with a current sexually transmitted infection (STI) </strong>(such as chlamydia, purulent cervicitis, or gonorrhoea infection):<ul><li>Arrange for the STI to be treated and provide advice on safe sex. For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/chlamydia-uncomplicated-genital/\">Chlamydia - uncomplicated genital</a> and <a class=\"topic-reference external-reference\" href=\"/topics/gonorrhoea/\">Gonorrhoea</a>.</li><li>Advise that the following methods are safe to use, but to avoid sexual intercourse (including oral sex) until she and her partner(s) have completed treatment:<ul><li>Progestogen-only pill (POP), progestogen-only implants, and progestogen-only injectables.</li><li>Combined hormonal contraceptives (pill, patch and vaginal ring).</li><li>Copper intrauterine device (Cu-IUD) or levonorgestrel intrauterine system (LNG-IUS) if continuing to use them. </li></ul></li><li>Do not start the following methods:<ul><li>Cu-IUD or LNG-IUS.</li><li>Sterilization — delay until the condition has resolved. After treatment, perform a pelvic examination to rule out recurrent or persistent infection.</li></ul></li></ul></li><li><strong>For women with vaginitis, other STIs (excluding HIV and hepatitis), and increased risk of STIs:</strong><ul><li>All methods can be used.</li></ul></li><li><strong>For women with a history of pelvic inflammatory disease (PID) and with no current risk factors for sexually transmitted infection (STI):</strong><ul><li>All methods can be used.</li></ul></li><li><strong>For women with current PID:</strong><ul><li>Advise the woman to use of one of the following methods:<ul><li>Barrier methods (condoms, diaphragms, and caps).</li><li>POP, progestogen-only implants, or progestogen-only injectables.</li><li>Combined hormonal contraceptives (pill, transdermal patch and vaginal ring).</li><li>Cu-IUD or LNG-IUS — these can be left in place if the woman already has one fitted.</li></ul></li><li>Do not start the following methods:<ul><li>Cu-IUD or LNG-IUS.</li><li>Sterilization — delay until the condition has resolved. After treatment, perform a pelvic examination to rule out recurrent or persistent infection.</li></ul></li></ul></li></ul><!-- end field 8729dbe4-4381-4dd2-94bb-6c4969f89730 --><!-- end item 9b95e29e-7cd7-4fbe-be64-35b80bbc5ff7 -->","subChapters":[{"id":"36a152eb-af90-5173-a7c8-3f321e05595a","slug":"basis-for-recommendation-425","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 046e3627-5300-4382-a9ca-d0402fe4c3f2 --><h4>Basis for recommendation</h4><!-- end field 046e3627-5300-4382-a9ca-d0402fe4c3f2 -->","summary":null,"htmlStringContent":"<!-- begin item 425fe451-d922-4425-bdab-b4319ed033ec --><!-- begin field adc29264-1ac3-46bd-9832-c5d8d45bd85c --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) guideline <em>UK Medical Eligibility Criteria for contraceptive Use</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2016</a>] and the World Health Organization (WHO) guidance <em>Medical eligibility for contraceptive use</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">WHO, 2015</a>].</p><!-- end field adc29264-1ac3-46bd-9832-c5d8d45bd85c --><!-- end item 425fe451-d922-4425-bdab-b4319ed033ec -->","subChapters":[]}]},{"id":"823ab3f2-f46e-5475-af53-d68a16c94937","slug":"obesity","fullItemName":"Obesity","depth":3,"htmlHeader":"<!-- begin field b2e4489e-aadf-4310-b928-3639b2af4242 --><h3>What methods of contraception are suitable for a woman who is obese?</h3><!-- end field b2e4489e-aadf-4310-b928-3639b2af4242 -->","summary":null,"htmlStringContent":"<!-- begin item edf11ee1-dbde-46c6-bb52-4d057a9c55f8 --><!-- begin field 4beb1b08-b2ff-4b4c-8d4e-b5b9925c3445 --><p><strong>If the woman's body mass index (BMI) is 30 kg/m<sup>2 </sup>or more, or 34 kg/m<sup>2</sup> or less:</strong></p><ul><li>All methods can be used. However, be aware that:<ul><li>Severe obesity may make diaphragms and caps difficult to fit.<ul><li>Advise women using the diaphragm to seek advice regarding diaphragm fitting if they gain or lose 3 kg or more in weight.</li></ul></li><li>In obese women, sterilization may be more difficult to perform, and there is an increased risk of complications such as wound infection (WHOMEC C).</li></ul></li></ul><p><strong>If the woman's BMI is 35 kg/m<sup>2 </sup>or more:</strong></p><ul><li>Discuss the following methods of contraception, taking into account her personal circumstances, and how important it is that she avoids pregnancy:<ul><li>Barrier methods (condoms, diaphragms, and caps).<ul><li>However, be aware that severe obesity may make diaphragms and caps difficult to fit.</li><li>Advise woman using the diaphragm to seek advice regarding diaphragm fitting if they gain or lose 3 kg or more in weight.</li></ul></li><li>Progestogen-only pill (POP), progestogen-only injectables, or progestogen-only implant.</li><li>Copper intrauterine device (Cu-IUD) is the most effective form of contraception.</li><li>Female sterilization — sterilization may be more difficult to perform, and there is an increased risk of complications such as wound infection (WHOMEC C).</li></ul></li><li>Consider combined hormonal contraception (pill, transdermal patch, or vaginal ring) only after seeking specialist advice.</li></ul><p><strong>In addition, note that:</strong></p><ul><li>For women who weigh more than 90 kg — the combined contraceptive patch should not be used if there are other suitable methods, as efficacy may be reduced.</li><li>For 'heavier women' — the progestogen-only contraceptive implant may need to be replaced earlier than the licensed 3 years.</li><li>Women with obesity should be informed that:<ul><li>Combined hormonal contraception use is associated with an increased risk of VTE.</li><li>Combined hormonal contraception use is associated with a small increased risk of myocardial infarction and ischaemic stroke.</li><li>If BMI is ≥35 kg/m2 the risks associated with use of combined hormonal contraception generally outweigh the benefits</li><li>If the woman has additional risk factors (such as smoking or hypertension) then these need to be taken into account when deciding upon a suitable method. For more information, see the section on  <a class=\"topic-reference internal-reference\" href=\"/topics/contraception-assessment/management/comorbidities-special-situations/#multiple-risk-factors-for-cardiovascular-disease\">Multiple risk factors for cardiovascular disease?</a>.</li></ul></li></ul><!-- end field 4beb1b08-b2ff-4b4c-8d4e-b5b9925c3445 --><!-- end item edf11ee1-dbde-46c6-bb52-4d057a9c55f8 -->","subChapters":[{"id":"7f27d2fd-1674-578a-94ab-6742ebaa3512","slug":"basis-for-recommendation-497","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field fda77ac8-a401-438b-a74b-0e7ed20c42be --><h4>Basis for recommendation</h4><!-- end field fda77ac8-a401-438b-a74b-0e7ed20c42be -->","summary":null,"htmlStringContent":"<!-- begin item 497a13a0-040d-40c5-a58e-d7bc86c3704b --><!-- begin field f9d94295-8a1b-4d21-ba61-a05bc9b54839 --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) <em>UK Medical Eligibility Criteria for Contraceptive Use</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2016</a>]; the FSRH clinical guidelines <em>Combined hormonal contraception</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2012</a>], the Faculty of Sexual and Reproductive Healthcare (FSRH) guidelines <em>Overweight, Obesity and Contraception</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2019</a>], <em>Progestogen-only implants</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2014b</a>], and <em>Progestogen-only pills</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2015d</a>]; the World Health Organization (WHO) guidance <em>Medical eligibility for contraceptive use </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">WHO, 2015</a>]; and the manufacturer's Summaries of Product Characteristics for Evra® and Nexplanon® [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">ABPI, 2016c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">ABPI, 2016d</a>].</p><ul><li>The manufacturers of Evra® advise that the contraceptive efficacy of the patch may be reduced in women weighing 90 kg or more [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">ABPI, 2016c</a>].</li><li>The manufacturers of Nexplanon® advise earlier replacement of the implant in 'heavier women', but do not provide guidance on the body mass index (BMI) above which the implant should be replaced earlier [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">ABPI, 2016d</a>].</li></ul><!-- end field f9d94295-8a1b-4d21-ba61-a05bc9b54839 --><!-- end item 497a13a0-040d-40c5-a58e-d7bc86c3704b -->","subChapters":[]}]},{"id":"dfbf024d-77d0-5224-bcb7-e6dbd3b24c85","slug":"hypertension","fullItemName":"Hypertension","depth":3,"htmlHeader":"<!-- begin field ea29ac35-e927-4863-bd5e-8a3bff223240 --><h3>What methods of contraception are suitable for a woman with hypertension?</h3><!-- end field ea29ac35-e927-4863-bd5e-8a3bff223240 -->","summary":null,"htmlStringContent":"<!-- begin item 9ba9b187-f137-4e7e-985f-87ac7dd119a6 --><!-- begin field 1058ea7c-ec87-4ae7-8aa2-4888a870822c --><ul><li><strong>If the woman has adequately controlled hypertension:</strong><ul><li>Discuss the following methods of contraception, taking into account her personal circumstances, and how important it is that she avoids pregnancy:<ul><li>Barrier methods (condoms, diaphragms, and caps). </li><li>Copper intrauterine device (Cu-IUD) or the levonorgestrel intrauterine system (LNG-IUS).</li><li>Progestogen-only pill (POP), progestogen-only implant, or progestogen-only injectable.</li><li>Female sterilization (WHOMEC C).</li></ul></li><li>Consider combined hormonal contraception (pill, transdermal patch, and vaginal ring) only after seeking specialist advice, as the risks usually outweigh the benefits.<ul></ul></li></ul></li><li><strong>If the woman has consistently elevated blood pressure </strong>(systolic is 140–159 mmHg or diastolic is 90–99mmHg):<ul><li>Discuss the following methods of contraception, taking into account her personal circumstances, and how important it is that she avoids pregnancy:<ul><li>Barrier methods (condoms, diaphragms, and caps).</li><li>Cu-IUD or LNG-IUS.</li><li>POP, progestogen-only implant, or progestogen-only injectable.</li><li>Female sterilization (WHOMEC C) — there are increased anaesthesia-related risks and an increased risk of cardiac arrhythmia with uncontrolled hypertension. </li></ul></li><li>Consider combined hormonal contraception only after seeking specialist advice, as the risks usually outweigh the benefits.</li></ul></li><li><strong>If the woman has consistently elevated blood pressure </strong>(systolic is 160 mmHg or more, or diastolic is 100 mmHg or more): <ul><li>Discuss the following methods of contraception, taking into account her personal circumstances, and how important it is that she avoids pregnancy:<ul><li>Barrier methods.</li><li>Cu-IUD or LNG-IUS.</li><li>POP, progestogen-only implant, or progestogen-only injectable.</li></ul>Consider the following methods only after seeking specialist advice:<ul><li>Female sterilization (WHOMEC S) — there are increased anaesthesia-related risks and an increased risk of cardiac arrhythmia with uncontrolled hypertension. </li></ul></li><li>Do not use combined hormonal contraception, due to the unacceptable health risk.</li></ul></li><li><strong>If the woman has hypertension and vascular disease:</strong><ul><li>Discuss the following methods of contraception, taking into account her personal circumstances, and how important it is that she avoids pregnancy:<ul><li>Barrier methods.</li><li>Cu-IUD or LNG-IUS. </li><li>POP or progestogen-only implant.</li></ul></li><li>Consider the following methods only after seeking specialist advice:<ul><li>Progestogen-only injectables.</li><li>Female sterilization (WHOMEC S).</li></ul></li><li>Do not use combined hormonal contraception, due to the unacceptable health risk.</li></ul></li></ul><!-- end field 1058ea7c-ec87-4ae7-8aa2-4888a870822c --><!-- end item 9ba9b187-f137-4e7e-985f-87ac7dd119a6 -->","subChapters":[{"id":"67f912f0-2f42-5337-84a7-6eebca260115","slug":"basis-for-recommendation-46f","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 52817abc-d8f4-4b6d-a7dd-2515abcee198 --><h4>Basis for recommendation</h4><!-- end field 52817abc-d8f4-4b6d-a7dd-2515abcee198 -->","summary":null,"htmlStringContent":"<!-- begin item 46fb25b0-7df8-43f8-8cb5-fee72cb1d317 --><!-- begin field 8f64f4ec-4a3a-47d8-9935-0f3d19c79d03 --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2016</a>] and the World Health Organization (WHO) guidance <em>Medical eligibility for contraceptive use</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">WHO, 2015</a>].</p><!-- end field 8f64f4ec-4a3a-47d8-9935-0f3d19c79d03 --><!-- end item 46fb25b0-7df8-43f8-8cb5-fee72cb1d317 -->","subChapters":[]}]},{"id":"e2196859-aa81-5dcb-be90-e6cc66286c28","slug":"venous-thromboembolism","fullItemName":"Venous thromboembolism","depth":3,"htmlHeader":"<!-- begin field f37516e4-65e6-466d-85d4-e87510152009 --><h3>What methods of contraception are suitable for a woman with a history of venous thromboembolism (VTE)?</h3><!-- end field f37516e4-65e6-466d-85d4-e87510152009 -->","summary":null,"htmlStringContent":"<!-- begin item 7623a9ef-4177-4d12-a6eb-0991169560c0 --><!-- begin field ae5da252-95da-44a4-9d97-deab990a3da1 --><ul><li><strong>For a woman with a </strong><strong>history of venous thromboembolism (VTE),</strong> <strong>known thrombogenic mutations, or who is taking anticoagulants for current VTE:</strong><ul><li>Discuss the following methods of contraception, taking into account her personal circumstances, and how important it is that she avoids pregnancy: <ul><li>Barrier method (condom, diaphragm, or cap).</li><li>Copper intrauterine device (Cu-IUD) or levonorgestrel intrauterine system (LNG-IUS).</li><li>Progestogen-only pill (POP), progestogen-only implant or progestogen-only injectable.</li><li>Sterilization — only if she is not taking anticoagulants (WHOMEC A).</li></ul></li><li>Advise the woman <em>not to</em> use the following methods:<ul><li>Combined hormonal contraceptives (pill, transdermal patch or vaginal ring).</li><li>Sterilization — if she is taking anticoagulants for current VTE (WHOMEC S). </li></ul></li></ul></li></ul><!-- end field ae5da252-95da-44a4-9d97-deab990a3da1 --><!-- end item 7623a9ef-4177-4d12-a6eb-0991169560c0 -->","subChapters":[{"id":"52171b0f-98aa-563e-9300-d0ab7c3f49fa","slug":"basis-for-recommendation-35a","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 76258615-dcd9-449e-9cb0-2f31c35e3678 --><h4>Basis for recommendation</h4><!-- end field 76258615-dcd9-449e-9cb0-2f31c35e3678 -->","summary":null,"htmlStringContent":"<!-- begin item 35a64a56-4195-402a-9ba6-3b45d6543d57 --><!-- begin field 19c76a06-9ca1-497e-8d77-1bdc994b9742 --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) guideline <em>UK Medical Eligibility Criteria for Contraceptive Use </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2016</a>]<em> </em>and the World Health Organization (WHO) guidance <em>Medical eligibility for contraceptive use</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">WHO, 2015</a>].</p><!-- end field 19c76a06-9ca1-497e-8d77-1bdc994b9742 --><!-- end item 35a64a56-4195-402a-9ba6-3b45d6543d57 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}